This document is a new patent application (US20260083677A1) filed by Astellas Pharma Inc. with the USPTO. The application details a novel solid medicinal form that includes at least one active ingredient and a pharmaceutically compatible, water-soluble drying agent, such as trimagnesium dicitrate or calcium chloride. Key characteristics of the claimed form include a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less, with a specific focus on formulations containing moisture-sensitive active ingredients.

This filing does not impose new regulatory obligations on pharmaceutical companies. However, it represents a new intellectual property filing that could impact future drug development and manufacturing processes within the pharmaceutical sector. Companies involved in drug formulation and stability research should be aware of this patent application as it may relate to their own product development and patent strategies.